Literature DB >> 7512773

Corticotropin-releasing factor and neuropeptide Y: role in emotional integration.

M Heilig1, G F Koob, R Ekman, K T Britton.   

Abstract

The amygdala complex integrates stressful stimuli and is critical in transducing their aversive value into autonomic, endocrine and behavioural responses. Stimulation within the amygdala complex produces signs of fear without a relevant external object, while lesions in this region abolish normal fear responses. In a manner characteristic of phylogenetically old limbic brain areas, the complex neurochemical anatomy of the amygdala involves a large number of phylogenetically old peptide mediators. The distribution and connectivity of these peptide systems have been extensively studied, but less is known about their functional role. Recent evidence suggests that two neuropeptides, corticotropin-releasing factor (CRF) and neuropeptide Y (NPY) exert a reciprocal regulation of responsiveness to stressful stimuli, possibly via an interaction of these two systems in the amygdala.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512773     DOI: 10.1016/0166-2236(94)90079-5

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  84 in total

Review 1.  Functional genomics strategies to identify susceptibility genes and treatment targets in alcohol dependence.

Authors:  Markus Heilig; Wolfgang Sommer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 2.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

3.  The Neurobiology of Addiction: Where We Have Been and Where We Are Going.

Authors:  George F Koob; Eric J Simon
Journal:  J Drug Issues       Date:  2009-01

Review 4.  Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse.

Authors:  George R Breese; Rajita Sinha; Markus Heilig
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

Review 5.  Stress, dysregulation of drug reward pathways, and the transition to drug dependence.

Authors:  George Koob; Mary Jeanne Kreek
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

Review 6.  Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework.

Authors:  George F Koob; Ian M Colrain
Journal:  Neuropsychopharmacology       Date:  2019-06-24       Impact factor: 7.853

7.  Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype.

Authors:  Cigdem Aydin; Ozge Oztan; Ceylan Isgor
Journal:  Behav Brain Res       Date:  2011-04-08       Impact factor: 3.332

Review 8.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

Review 9.  Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Signaling and the Dark Side of Addiction.

Authors:  Olivia W Miles; Victor May; Sayamwong E Hammack
Journal:  J Mol Neurosci       Date:  2018-08-03       Impact factor: 3.444

10.  Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking.

Authors:  Andrea Cippitelli; Ruslan Damadzic; Anita C Hansson; Erick Singley; Wolfgang H Sommer; Robert Eskay; Annika Thorsell; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2009-12-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.